Recent advances on anti-HIV vaginal delivery systems development

Advanced Drug Delivery Reviews

Volumn 92, Issue , 2015, Pages 123-145

  Antimisiaris, Sophia G ^a,b   Mourtas, Spyridon ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b INSTITUTE OF CHEMICAL ENGINEERING SCIENCES   (Greece)

Author keywords

AIDS; Formulation; HIV; Microbicides; Mucosal; Nanotechnology; Transmission; Vaginal

Indexed keywords

NANOTECHNOLOGY;

AIDS; FORMULATION; MICROBICIDES; MUCOSAL; VAGINAL;

TRANSMISSIONS;

1 [5 (4 FLUOROBENZYL) 2 FURYL] 3 (1,2,4 TRIAZOL 3 YL) 1,3 PROPANEDIONE; 4 BENZOYL 1 [(4 METHOXY 1H PYRROLO[2,3 B]PYRIDIN 3 YL)OXOACETYL] 2 METHYLPIPERAZINE; ANTIVIRUS AGENT; ASTODRIMER; BENZALKONIUM CHLORIDE; C 731; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CYANOVIRIN N; DAPIVIRINE; DENDRIMER; ENFUVIRTIDE; IBALIZUMAB; INTEGRASE INHIBITOR; LIPOSOME; MICROBICIDE; MONOCLONAL ANTIBODY 2F5; MONOCLONAL ANTIBODY 4E10; N [3 [4 (3 BENZYL 1 ETHYL 5 PYRAZOLYL) 1 PIPERIDINYLMETHYL] 4 (3 FLUOROPHENYL)CYCLOPENTYL] N METHYLVALINE; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; PHI 236; PHI 346; PHI 443; PLERIXAFOR; PRO 140; SOLID LIPID NANOPARTICLE; TENOFOVIR; TIFUVIRTIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; AGENTS USED INTRAVAGINALLY; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; NANOPARTICLE;

CD4+ T LYMPHOCYTE; CELL EXPANSION; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; DRUG STABILITY; DRUG TOLERABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; INTRAVAGINAL DRUG ADMINISTRATION; LANGERHANS CELL; MIXED INFECTION; NANOTECHNOLOGY; NONHUMAN; PHYSICAL CHEMISTRY; PREVENTIVE MEDICINE; PRIORITY JOURNAL; REVIEW; SEXUAL TRANSMISSION; SEXUALLY TRANSMITTED DISEASE; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SUPPOSITORY; UTERINE ENDOCERVIX; VAGINA FLORA; VAGINA MUCOSA; VIRION; VIRUS TRANSMISSION; VISCOSITY; DRUG ABSORPTION; FEMALE; HIV INFECTIONS; PHYSIOLOGY; PROCEDURES; TRANSMISSION; VAGINA;

ADMINISTRATION, INTRAVAGINAL; ANTI-HIV AGENTS; DRUG DELIVERY SYSTEMS; FEMALE; HIV INFECTIONS; HUMANS; NANOPARTICLES; VAGINA; VAGINAL ABSORPTION; VAGINAL CREAMS, FOAMS, AND JELLIES;

EID: 84943448454     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2015.03.015     Document Type: Review

References (346)

1. Fauci A.S., Folkers G.K., Dieffenbach C.W. HIV-AIDS: Much accomplished, much to do. Nat. Immunol. 2013, 14(11):1104-1107.
2. Kallings L.O. The first postmodern pandemic: 25years of HIV/ AIDS. J. Intern. Med. 2008, 263(3):218-243.
3. Holmes C.B., Losina E., Walensky R.P., Yazdanpanah Y., Freedberg K.A. Review of human immunodeficiency virus type 1-related opportunistic infections in sub-Saharan Africa. Clin. Infect. Dis. 2003, 36(5):652-662.
4. Holmes C.B., Wood R., Badri M., Zilber S., Wang B., Maartens G., et al. CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. JAIDS 2006, 42(4):464-469.
5. Nuttall J., Romano J., Douville K., Galbreath C., Nel A., Heyward W., et al. The future of HIV prevention: Prospects for an effective anti-HIV microbicide. Infect. Dis. Clin. N. Am. 2007, 21:219-239.
6. Hladik F., Doncel G.F. Preventing mucosal HIV transmission with topical microbicides: challenges and opportunities. Antivir. Res. 2010, 88(Suppl. 1):S3-S9.
7. Shattock R.J., Moore J.P. Inhibiting sexual transmission of HIV-1 infection. Nat. Rev. Microbiol. 2003, 1(1):25-34.
8. Shattock R.J., Rosenberg Z. Microbicides: topical prevention against HIV. Cold Spring Harb. Perspect. Med. 2012, 2:a007385.
9. Saba E., Grivel J.V., Vanpouille C., Brichacek B., Fitzgerald W., Margolis L., et al. HIV-1 sexual transmission: early events of HIV-1 infection of human cervico-vaginal tissue in an optimized ex vivo model. Mucosal Immunol. 2010, 3(3):280-290.
10. Miyauchi K., Kim Y., Latinovic O., Morozov V., Melikyan G.B. HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes. Cell 2009, 137(3):433-444.
11. Haase A.T. Targeting early infection to prevent HIV-1 mucosal transmission. Nature 2010, 464:217-223.
12. Li G., Cheng M., Nunoya J., Cheng L., Guo H., Yu H., et al. Plasmacytoid dendritic cells suppress HIV-1 replication but contribute to HIV-1 induced immunopathogenesis in humanized mice. PLoS Pathog. 2014, 10(7):e1004291.
13. Hladik F., McElrath M.J. Setting the stage: host invasion by HIV. Nat. Rev. Immunol. 2008, 8(6):447-457.
14. Hladik F., Hope T.J. HIV infection of the genital mucosa in women. Curr. HIV/AIDS Rep. 2009, 6(1):20-28.
15. Sallé B., Brochard P., Bourry O., Mannioui A., Andrieu T., Prevot S., et al. Infection of macaques after vaginal exposure to cell-associated simian immunodeficiency virus. J. Infect. Dis. 2010, 202(3):337-344.
16. Dosekun O., Fox J. An overview of the relative risks of different sexual behaviours on HIV transmission. Curr. Opin. HIV AIDS 2010, 5(4):291-297.
17. Keele B.F., Giorgi E.E., Salazar-Gonzalez J.F., Decker J.M., Pham K.T., Salazar M.G., et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl. Acad. Sci. 2008, 105(21):7552-7557.
18. Salazar-Gonzalez J.F., Salazar M.G., Keele B.F., Learn G.H., Giorgi E.E., Li H., et al. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J. Exp. Med. 2009, 206(6):1273-1289.
19. Keele B.F. Identifying and characterizing recently transmitted viruses. Curr. Opin. HIV AIDS 2010, 5(4):327-334.
20. Haaland R.E., Hawkins P.A., Salazar-Gonzalez J., Johnson A., Tichacek A., Karita E., et al. Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype a and C HIV-1. PLoS Pathog. 2009, 5(1):e1000274.
21. Haase A.T. Early events in sexual transmission of HIV and SIV and opportunities for interventions. Annu. Rev. Med. 2011, 62:127-139.
22. Voeten H.A., Vissers D.C., Gregson S., Zaba B., White R.G., de Vlas S.J., et al. Strong association between in-migration and HIV prevalence in urban sub-Saharan Africa. Sex. Transm. Dis. 2010, 37(4):240-243.
23. Wang L., Wang L., Smith M.K., Li L.M., Ming S., Lü J., et al. Heterosexual transmission of HIV and related risk factors among serodiscordant couples in Henan province China. Chin. Med. J. 2013, 126(19):3694-3700.
24. Tevi-Benissan C., Belec L., Levy M., Schneider-Fauveau V., Si Mohamed A., Hallouin M.C., et al. In vivo semen-associated pH neutralization of cervicovaginal secretions. Clin. Diagn. Lab. Immunol. 1997, 4:367-374.
25. Kim P.S., Read S.W. Nanotechnology and HIV: potential applications for treatment and prevention. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2010, 2(6):693-702.
26. Berlier W., Bourlet T., Lawrence P., Hamzeh H., Lambert C., Genin C., et al. Selective sequestration of X4 isolates by human genital epithelial cells: Implication for virus tropism selection process during sexual transmission of HIV. J. Med. Virol. 2005, 77:465-474.
27. Malkovsky M., Newell A., Dalgleish A.G. Inactivation of HIV by nonoxynol-9. Lancet 1988, 1(8586):645.
28. Van Damme L., Ramjee G., Alary M., Vuylsteke B., Chandeying V., Rees H., et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 2002, 360:971-977.
29. Hillier S.L., Moench T., Shattock R., Black R., Reichelderfer P., Veronese F. In vitro and in vivo: The story of nonoxynol 9. J. Acquir. Immune Defic. Syndr. 2005, 39:1-8.
30. O'Connor T.J., Kinchington D., Kangro H.O., Jeffries D.J. The activity of candidate virucidal agents, low pH and genital secretions against HIV-1 in vitro. Int. J. STD AIDS 1995, 6:267-272.
31. Mayer K.H., Peipert J., Fleming T., Fullem A., Moench T., Cu-Uvin S., et al. Safety and tolerability of BufferGel, a novel vaginal microbicide, in women in the United States. Clin. Infect. Dis. 2001, 32:476-482.
32. Ramjee G. Microbicide research: current and future directions. Curr. Opin. HIV AIDS 2010, 5:316-321.
33. Fletcher P.S., Shattock R.J. PRO-2000, an antimicrobial gel for the potential prevention of HIV infection. Curr. Opin. Investig. Drugs 2008, 9:189-200.
34. Cameron P.U., Freudenthal P.S., Barker J.M., Gezelter S., Inaba K., Steinman R.M. Dendritic cells exposed to human immunodeficiency virus type-1 transmit a vigorous cytopathic infection to CD4+ T cells. Science 1992, 257:383-387.
35. Wu L., KewalRamani V.N. Dendritic-cell interactions with HIV: infection and viral dissemination. Nat. Rev. Immunol. 2006, 6:859-868.
36. Hladik F., Sakchalathorn P., Ballweber L., Lentz G., Fialkow M., Eschenbach D., et al. Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity 2007, 26:257-270.
37. Hu Q., Frank I., Williams V., Santos J.J., Watts P., Griffin G.E., et al. Blockade of attachment and fusion receptors inhibits HIV-1 infection of human cervical tissue. J. Exp. Med. 2004, 199:1065-1075.
38. Bobardt M.D., Chatterji U., Selvarajah S., Van der Schueren B., David G., Kahn B., et al. Cell-free human immunodeficiency virus type 1 transcytosis through primary genital epithelial cells. J. Virol. 2007, 81:395-405.
39. Bomsel M. Transcytosis of infectious human immunodeficiency virus across a tight human epithelial cell line barrier. Nat. Med. 1997, 3:42-47.
40. Dezzutti C.S., Guenthner P.C., Cummins J.E., Jr T. Cabrera, J.H. Marshall, A. Dillberger, et al., Cervical and prostate primary epithelial cells are not productively infected but sequester human immunodeficiency virus type 1. J. Infect. Dis. 2001, 183:1204-1213.
41. Wu Z., Chen Z., Phillips D.M. Human genital epithelial cells capture cell-free human immunodeficiency virus type 1 and transmit the virus to CD4+ Cells: implications for mechanisms of sexual transmission. J. Infect. Dis. 2003, 188:1473-1482.
42. Abel K., Rocke D.M., Chohan B., Fritts L., Miller C.J. Temporal and anatomic relationship between virus replication and cytokine gene expression after vaginal simian immunodeficiency virus infection. J. Virol. 2005, 79:12164-12172.
43. Fontenot D., He H., Hanabuchi S., Nehete P.N., Zhang M., Chang M., et al. TSLP production by epithelial cells exposed to immunodeficiency virus triggers DC-mediated mucosal infection of CD4+ T cells. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:16776-16781.
44. Ziegler S.F., Artis D. Sensing the outside world: TSLP regulates barrier immunity. Nat. Immunol. 2010, 11:289-293.
45. Thurman A.R., Doncel G.F. Innate immunity and inflammatory response to trichomonas vaginalis and bacterial vaginosis: Relationship to HIV acquisition. Am. J. Reprod. Immunol. 2011, 65(2):89-98.
46. Lavelle E.C., Murphy C., O'Neill L.A., Creagh E.M. The role of TLRs, NLRs, and RLRs in mucosal innate immunity and homeostasis. Mucosal Immunol. 2010, 3:17-28.
47. Thurman A.R., Clark M.R., Doncel G.F. Multipurpose prevention technologies: biomedical tools to prevent HIV-1, HSV-2, and unintended pregnancies. Infect. Dis. Obstet. Gynecol. 2011, 2011:1-10.
48. Mares D., Simoes J.A., Novak R.M., Spear G.T. TLR2-mediated cell stimulation in bacterial vaginosis. J. Reprod. Immunol. 2008, 77:91-99.
49. Trifonova R.T., Doncel G.F., Fichorova R.N. Polyanionic microbicides modify Toll-like receptor-mediated cervicovaginal immune responses. Antimicrob. Agents Chemother. 2009, 53:1490-1500.
50. Gebhardt T., Wakim L.M., Eidsmo L., Reading P.C., Heath W.R., Carbone F.R. Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus. Nat. Immunol. 2009, 10:524-530.
51. Zhu J., Hladik F., Woodward A., Klock A., Peng T., Johnston C., et al. Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat. Med. 2009, 15:886-892.
52. Celum C., Wald A., Hughes J., Sanchez J., Reid S., Delany-Moretlwe S., et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet 2008, 371:2109-2119.
53. Li N., Chen Y., He W., Yi T., Zhao D., Zhang C., et al. Anti-CD3 preconditioning separates GVL from GVHD via modulating host dendritic cell and donor T-cell migration in recipients conditioned with TBI. Blood 2009, 113:953-962.
54. Johnson V.A., Brun-Vezinet F., Clotet B., Gunthard H.F., Kuritzkes D.R., Pillay D., et al. Update of the drug resistance mutations in HIV-1: December. Top. HIV Med. 2009, 17:138-145.
55. Ramjee G., Doncel G.F., Mehendale S., Tolley E.E., Dickson K. Microbicides 2008 Conference: From discovery to advocacy. AIDS Res. Ther. 2008, 5:19.
56. McElrath M.J., Ballweber L., Terker A., Kreger A., Sakchalathorn P., Robinson B., et al. Ex vivo comparison of microbicide efficacies for preventing HIV-1 genomic integration in intraepithelial vaginal cells. Antimicrob. Agents Chemother. 2010, 54:763-772.
57. Hawkins T., Veikley W., Claire R.L.St, Guyer B., Clark N., Kearney B.P. Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. J. Acquir. Immune Defic. Syndr. 2005, 39:406-411.
58. King T., Bushman L., Kiser J., Anderson P.L., Ray M., Delahunty T., et al. Liquid chromatography-tandem mass spectrometric determination of tenofovir-diphosphate in human peripheral blood mononuclear cells. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2006, 843:147-156.
59. Kiser J.J., Aquilante C.L., Anderson P.L., King T.M., Carten M.L., Fletcher C.V. Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients. J. Acquir. Immune Defic. Syndr. 2008, 47:298-303.
60. Hendrix C.W., Cao Y.J., Fuchs E.J. Topical microbicides to prevent HIV: clinical drug development challenges. Annu. Rev. Pharmacol. Toxicol. 2009, 49:349-375.
61. Ramjee G., Kamali A., McCormack S. The last decade of microbicide clinical trials in Africa: From hypothesis to facts. AIDS 2010, 24:S40-S49.
62. Cruz O.J.D., Uckun F.M. Vaginal microbicides and their delivery platforms. Expert opinion on drug delivery 2014, 11,5:723-740.
63. Eckstein P., Jackson M.C., Millman N., Sobrero A.J. Comparison of vaginal tolerance tests of spermicidal preparations in rabbits and monkeys. J. Reprod. Fertil. 1969, 20:85-93.
64. Merbah M., Introini A., Fitzgerald W., Grivel J.C., Lisco A., Vanpouille C., et al. Cervico-vaginal tissue ex vivo as a model to study early events in HIV-1 infection. Am. J. Reprod. Immunol. 2011, 65:268-278.
65. Ariën K., Kyongo J.K., Vanham G. Ex vivo models of HIV sexual transmission and microbicide development. Curr. HIV Res. 2012, 10(1):73-78.
66. Ochsenbauer-Jambor C., Jones J., Heil M., Zammit K.P., Kutsch O. T-cell line for HIV drug screening using EGFP as a quantitative marker of HIV-1 replication. Biotechniques 2006, 40(1):91-100.
67. Lassen K.G., Hebbeler A.M., Bhattacharyya D., Lobritz M.A., Greene W.C. A flexible model of HIV-1 latency permitting evaluation of many primary CD4 T-cell reservoirs. PLoS ONE 2012, 7(1):e30176.
68. Westby M., Nakayama G.R., Butler S.L., Blair W.S. Cell-based and biochemical screening approaches for the discovery of novel HIV-1 inhibitors. Antivir. Res. 2005, 67:121-140.
69. Pavelic Z., Skalko-Basnet N., Schubert R., Jalsenjak I., Nejat D. Liposomal gels for vaginal drug delivery. Methods in enzymology 2004, 287-299. Academic Press.
70. Pavelic Z., Skalko-Basnet N., Filipovic-Grcic J., Martinac A., Jalsenjak I. Development and in vitro evaluation of a liposomal vaginal delivery system for acyclovir. J. Control. Release 2005, 106:34-43.
71. Pavelic Z., Skalko-Basnet N., Jalsenjak I. Characterisation and in vitro evaluation of bioadhesive liposome gels for local therapy of vaginitis. Int. J. Pharm. 2005, 301:140-148. (K.G. Lassen, A.M. Hebbeler, D. Bhattacharyya,).
72. Khanna N., Dalby R., Tan M., Arnold S., Stern J., Frazer N. Phase I/II clinical safety studies of terameprocol vaginal ointment. Gynecol. Oncol. 2007, 107:554-562.
73. Joshi S., Joglekar N., Ghate M., Unni J., Risbud A., Bentley M., et al. Phase I safety & preliminary acceptability of nonoxynol-9 vaginal pessary as a vaginal microbicide in low risk women in Pune, India. Indian J. Med. Res. 2003, 117:152-157.
74. Raymond E.G., Chen P.L., Luoto J. Spermicide trial group, contraceptive effectiveness and safety of five nonoxynol-9 spermicides: A randomized trial. Obstet. Gynecol. 2004, 103:430-439.
75. Tien D., Schnaare R.L., Kang F., Cohl G., McCormick T.J., Moench T.R., et al. In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials. AIDS Res. Hum. Retrovir. 2005, 21:845-853.
76. Behets F.M., Turner A.N., Van Damme K., Rabenja N.L., Ravelomanana N., Swezey T.A., et al. Vaginal microbicide and diaphragm Use for sexually transmitted infection prevention: A randomized acceptability and feasibility study among high- risk women in Madagascar. Sex. Transm. Dis. 2008, 35:818-826.
77. Keller M.J., Carpenter C.A., Lo Y., Einstein M.H., Liu C., Fredricks D.N., et al. Phase I randomized safety study of twice daily dosing of acidform vaginal gel: Candidate antimicrobial contraceptive. PLoS ONE 2012, 7(10):e46901.
78. Bentley M.E., Fullem A.M., Tolley E.E., Kelly C.W., Jogelkar N., Srirak N., et al. Acceptability of a microbicide among women and their partners in a 4-country phase I trial. Am. J. Public Health 2004, 94:1159-1164.
79. Ballagh A., Brache A., Mauck C., Callahan M.A., Cochon L., Wheeless A., et al. A Phase I study of the functional performance, safety and acceptability of the BufferGel® DuetTM. Contraception 2008, 77:130-137.
80. Ballagh S.A., Brache V., Mauck C., Callahan M.M., Cochon L., Wheeless A., et al. A Phase I study of the functional performance, safety and acceptability of the BufferGel Duet. Contraception 2008, 77:130-137.
81. Feldblum P.J., Adeiga A., Bakare R., Wevill S., Lendvay A., Obadaki F., et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS ONE 2008, 3(1):e1474.
82. Van Damme L., Govinden R., Mirembe F.M., Guedou F., Solomon S., Becker M.L., et al. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N. Engl. J. Med. 2008, 359:463-472.
83. Malonza I.M., Mirembe F., Nakabiito C., Odusoga L.O., Osinupebi O.A., Hazari K., et al. Expanded Phase I safety and acceptability study of 6% cellulose sulfate vaginal gel. Aids 2005, 19:2157-2163.
84. Van de Wijgert J.H., Braunstein S.L., Morar N.S., Jones H.E., Madurai L., Strickfaden T.T., et al. Carraguard vaginal Gel safety in HIV-positive women and Men in South Africa. J. Acquir. Immune Defic. Syndr. 2007, 46:538-546.
85. Kilmarx P.H., Blanchard K., Chaikummao S., Friedland B.A., Srivirojana N., Connolly C., et al. A randomized, placebo-controlled trial to assess the safety and acceptability of use of carraguard vaginal gel by heterosexual couples in Thailand. Sex. Transm. Dis. 2008, 35:226-232.
86. McGowan I., Gomez K., Bruder K., Febo I., Chen B.A., Richardson B.A., et al. Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel. AIDS 2011, 25:1057-1064.
87. Mbopi-Keou F.X., Trottier S., Omar R.F., Nkele N.N., Fokoua S., Mbu E.R., et al. A randomized, double-blind, placebo-controlled Phase II extended safety study of two Invisible Condom formulations in Cameroonian women. Contraception 2010, 81(1):79-85.
88. Cruz O.J.D., Uckun F.M. Preclinical and clinical profile of emmelle (dextrin-2-sulfate) - a potential anti-HIV microbicide. J. Appl. Res. 2005, 5(1):26-34.
89. Lacey C.J., Woodhall S., Qi Z., Sawant S., Cowen M., McCormack S., et al. Unacceptable side effects associated with a hyperosmolar vaginal microbicide in a phase 1 trial. Int. J. STD AIDS 2010, 21(10):714-717.
90. Karim Q.A., Karim S.S.A., Frohlich J.A., Grobler A.C., Baxter C., Mansoor L.E., et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010, 329:1168-1174.
91. Celum C., Baeten J.M. Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence. Curr. Opin. Infect. Dis. 2012, 25:51-57.
92. Person A.K., Hicks C.B. Pre-exposure prophylaxis - one more tool for HIV prevention. Curr. HIV Res. 2012, 10:117-122.
93. Schwartz J.L., Kovalevsky G., Lai J.J., Ballagh S.A., McCormick T., Douville K., et al. A randomized six-day safety study of an antiretroviral microbicide candidate UC781, a non-nucleoside reverse transcriptase inhibitor. Sex. Transm. Dis. 2008, 35:414-419.
94. Haaland R.E., Evans-Strickfaden T., Holder A., Pau C.P., McNicholl J.M., Chaikummao S., et al. UC781 microbicide gel retains anti-HIV activity in cervicovaginal lavage fluids collected following twice-daily vaginal application. Antimicrob. Agents Chemother. 2012, 56:3592-3596.
95. Vernazza P., Wang C., Pozniak A., Weil E., Pulik P., Cooper D.A., et al. Efficacy and safety of lersivirine (UK-453.061) versus efavirenz in antiretroviral treatment-naive HIV-1-infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, phase IIb trial. J. Acquir. Immune Defic. Syndr. 2013, 62(2):171-179.
96. Cates W. The NIH condom report: The glass is 90% full. Fam. Plann. Perspect. 2001, 33:231-233.
97. Pazoi K., Kramer M.R., Hogue C.J. Condoms for dual protection: patterns of use with highly effective contraceptive methods. Public Health Rep. 2010, 135:208-217.
98. Flannigan J. Promoting sexual health: practical guidance on male condom useNursing standard 2007, 21:51-57.
99. Balzarini J., Van Damme L. Intravaginal and intrarectal microbicides to prevent HIV infection. CMAJ 2005, 172(4):461-464.
100. Jr Buckheit R.W., Watson K.M., Morrow K.M., Ham A.S. Development of topical microbicides to prevent the sexual transmission of HIV. Antiviral Res. 2010, 85(1):142-158.
101. Wong H.L., Chattopadhyay N., Wu X.Y., Bendayan R. Nanotechnology application for improved delivery of antiretroviral drugs to the brain. Adv. Drug Deliv. Rev. 2010, 62:503-517.
102. Herrera C., Shattock R.J. Potential use of protease inhibitors as vaginal and colorectal microbicides. Curr. HIV Res. 2012, 10:42-52.
103. McGowan I. Microbicides: a new frontier in HIV prevention. Biologicals 2006, 34:241-255.
104. Teleshova N., Chang T., Profy A., Klotman M.E. Inhibitory effect of PRO 2000, a candidate microbicide, on dendritic cell-mediated HIV transfer. Antimicrob. Agents Chemother. 2008, 52(5):1751-1758.
105. Klebanoff S.J., Kazazi F. Inactivation of human immunodeficiency virus type 1 by the amine oxidase-peroxidase system. J. Clin. Microbiol. 1995, 33(8):2054-2057.
106. Adams J.J., Kashuda A.D.M. Best practice & research clinical obstetrics and gynaecology 2012, 26:451-462.
107. McCormack S., Ramjee G., Kamali A., Rees H., Crook A.M., Gafos M., et al. PRO2000 vaginal gel for prevention of HIV- 1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet 2010, 376:1329-1337.
108. Peterson L., Nanda K., Opoku B.K., Ampofo W.K., Owusu-Amoako M., Boakye A.Y., et al. SAVVY (C31G) gel for prevention of HIV infection in women: a Phase 3, double-blind, randomized, placebo-controlled trial in Ghana. PLoS ONE 2007, 2:e1312.
109. Pirrone V., Wigdahl B., Krebs F.C. The rise and fall of polyanionic inhibitors of the human immunodeficiency virus type 1. Antiviral Res. 2011, 90:168-182.
110. Karim S.S.A., Baxter C. Overview of microbicides for the prevention of human immunodeficiency virus. Best Pract. Res. Clin. Obstet. Gynaecol. 2012, 26:427-439.
111. Agarwal H.K., Kumar A., Doncel G.F., Parang K. Synthesis, antiviral and contraceptive activities of nucleoside-sodium cellulose sulfate acetate and succinate conjugates. Bioorg. Med. Chem. Lett. 2010, 20(23):6993-6997.
112. McCarthy T.D., Karellas P., Henderson S.A., Giannis M., O'Keefe D.F., Heery G., et al. Dendrimers as drugs: discovery and preclinical and clinical development of dendrimer-based microbicides for HIV and STI prevention. Mol. Pharm. 2005, 2:312-318.
113. Rupp R., Rosenthal S.L., Stanberry L.R. VivaGel (SPL7013 Gel): a candidate dendrimer-microbicide for the prevention of HIV and HSV infection. Int. J. Nanomedicine 2007, 2:561-566.
114. Tyssen D., Henderson S.A., Johnson A., Sterjovski J., Moore K., La J., et al. Structure activity relationship of dendrimer microbicides with dual action antiviral activity. PLoS ONE 2010, 5:e12309.
115. Telwatte S., Moore K., Johnson A., Tyssen D., Sterjovski J., Aldunate M., et al. Virucidal activity of the dendrimer microbicide SPL7013 against HIV-1. Antiviral Res. 2011, 90:195-199.
116. Reina J.J., Bernardi A., Clerici M., Rojo J. HIV microbicides: state-of-the-art and new perspectives on the development of entry inhibitors. Future Med. Chem. 2010, 2:1141-1159.
117. McGowan I., Gomez K., Bruder K., Febo I., Chen B.A., Richardson B.A., et al. Measurement of mucosal biomarkers in a phase 1 trial of intravaginal 3% StarPharma LTD 7013 gel (VivaGel) to assess expanded safety. J. Acquir. Immune Defic. Syndr. 2012, 59:134-140.
118. Cohen C.R., Brown J., Moscicki A.B., Bukusi E.A., Paull J.R., Price C.F., et al. A phase I randomized placebo controlled trial of the safety of 3% SPL7013 Gel(VivaGel) in healthy young women administered twice daily for 14days. PLoS ONE 2011, 6:e16258.
119. Moscicki A.B., Kaul R., Ma Y., Scott M.E., Daud I.I., Bukusi E.A., et al. Measurement of mucosal biomarkers in a phase 1 trial of intravaginal 3% StarPharma LTD 7013 gel (VivaGel) to assess expanded safety. J. Acquir. Immune Defic. Syndr. 2012, 59:134-140.
120. Patton D.L., Cosgrove Sweeney Y.T., McCarthy T.D., Hillier S.L. Preclinical safety and efficacy assessments of dendrimer-based (SPL7013) microbicide gel formulations in a nonhuman primate model. Antimicrob. Agents Chemother. 2006, 50:1696-1700.
121. Emau P., Tian B., O'keefe B.R., Mori T., McMahon J.B., Palmer K.E., et al. Griffithsin, a potent HIV entry inhibitor, is an excellent candidate for anti-HIV microbicide. J. Med. Primatol. 2007, 36(4-5):244-253.
122. Neurath A.R., Strick N., Li Y.Y. Water dispersible microbicidal cellulose acetate phthalate film. BMC Infect. Dis. 2003, 3:27.
123. Férir G., Gordts S.C., Schols D. HIV-1 and its resistance to peptidic carbohydrate-binding agents (CBAs): An overview. Molecules 2014, 19:21085-21112.
124. Veazey R.S., Ling B., Green L.C., Ribka E.P., Lifson J.D., Piatak M., et al. Topically applied recombinant chemokine analogues fully protect macaques from vaginal simianhuman immunodeficiency virus challenge. J. Infect. Dis. 2009, 199(10):1525-1527.
125. Veazey R.S., Ketas T.J., Dufour J., Moroney-Rasmussen T., Green L.C., Klasse P.J., et al. Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor. J. Infect. Dis. 2010, 202:739-744.
126. Neff C.P., Kurisu T., Ndolo T., Fox K., Akkina R. A topical microbicide gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu mice. PLoS ONE 2011, 6:e20209.
127. Gengiah T.N., Baxter C., Mansoor L.E., Kharsany A.B., Karim S.S.A. A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infection. Expert Opin. Invest. Drugs 2012, 21:695-715.
128. Mesquita P.M., Rastogi R., Segarra T.J., Teller R.S., Torres N.M., Huber A.M., et al. Intravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infection. J. Antimicrob. Chemother. 2012, 67:1730-1738.
129. Rosen R.K., Morrow K.M., Carballo-Dieguez A., Mantell J.E., Hoffman S., Gai F., et al. Acceptability of tenofovir gel as a vaginal microbicide among women in a phase I trial: a mixed-methods study. J. Women's Health (Larchmt) 2008, 17:383-392.
130. Karim Q.A., Karim S.S.A., Frohlich J.A., Grobler A.C., Baxter C., Mansoor L.E., et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010, 329:1168-1174.
131. Karim S.S., Kashuba A.D., Werner L., Karim Q.A. Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. Lancet 2011, 378:279-281.
132. Grammen C., Augustijns P., Brouwers J. In vitro profiling of the vaginal permeation potential of anti-HIV microbicides and the influence of formulation excipients. Antiviral Res. 2012, 96:226-233.
133. Damian F., Fabian J., Friend D.R., Kiser P.F. Approaches to improve the stability of the antiviral agent UC781 in aqueous solutions. Int. J. Pharm. 2010, 396:1-10.
134. Yang H., Parniak M.A., Isaacs C.E., Hillier S.L., Rohan L.C. Characterization of cyclodextrin inclusion complexes of the anti-HIV non-nucleoside reverse transcriptase inhibitor UC781. AAPS J. 2008, 10(4):606-613.
135. Rosenberg Z.F., Devlin B. Future strategies in microbicide development. Best Pract. Res. Clin. Obstet Gynaecol. 2012, 26:503-513.
136. Clark M.R., Johnson T.J., McCabe R.T., Clark J.T., Tuitupou A., Elgendy H., et al. A Hot-melt extruded intravaginal ring for the sustained delivery of the antiretroviral microbicide UC781. J. Pharm. Sci. 2012, 101(2):576-587.
137. Nel A.M., Coplan P., Smythe S.C., McCord K., Mitchnick M., Kaptur P.E., et al. Pharmacokinetic assessment of dapivirine vaginal microbicide gel in healthy, HIV-negative women. AIDS Res. Hum. Retrovir. 2010, 26:1181-1190.
138. Di Fabio S., Van Roey J., Giannini G., van den Mooter G., Spada M., Binelli A., et al. Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the nonnucleoside reverse transcriptase inhibitor TMC120 in a gel formulation. AIDS 2003, 17:1597-1604.
139. Caron M., Besson G. S.L-D. Etenna, A. Mintsa-Ndong, S. Mourtas, A. Radaelli, et al., Protective properties of non-nucleoside reverse transcriptase inhibitor (MC1220) incorporated into liposome against intravaginal challenge of Rhesus Macaques with RT-SHIV. Virology 2010, 405:225-233.
140. Kenney J., Aravantinou M., Singer R., Hsu M., Rodriguez A., Kizima L., et al. An antiretroviral/zinc combination gel provides 24h of complete protection against vaginal SHIV infection in macaques. PLoS ONE 2011, 6:e15835.
141. Fetherston S.M., Geer L., Veazey R.S., Goldman L., Murphy D.J., Ketas T.J., et al. Partial protection against multiple RT-SHIV162P3 vaginal challenge of rhesus macaques by a silicone elastomer vaginal ring releasing the NNRTI MC1220. J. Antimicrob. Chemother. 2013, 68:394-403.
142. Ham A.S., Rohan L.C., Boczar A., Yang L., Buckheit K.W., Buckheit R.W. Vaginal film drug delivery of the pyrimidinedione IQP-0528 for the prevention of HIV infection. Pharm. Res. 2012, 29:1897-1907.
143. Dobard C., Sharma S., Parikh U.M., West R., Taylor A., Martin A., et al. Postexposure protection of macaques from Vaginal SHIV infection by topical integrase inhibitors. Sci. Transl. Med. 2014, 6:227-235.
144. Wainberg M.A., Mespléde T., Quashie P.K. The development of novel HIV integrase inhibitors and the problem of drug resistance. Curr. Opin.Virol. 2012, 2(5):656-662.
145. Radonna J.T., Yie S.E.C., Fay H.Y., Susan E.V. Mutagenesis of protease cleavage sites in the HIV type 1 gagpolyprotein. J. Virol. 1991, 65:922-930.
146. Jardine D.K., Tyssen D.P., Birch C.J. Effect of protease inhibitors on HIV-1 maturation and infectivity. Antiviral Res. 2000, 45:59-68.
147. Wang Z., Bennett E.M., Wilson D.J., Salomon C., Vince R. Rationally designed dual inhibitors of HIV reverse transcriptase and integrase. J. Med. Chem. 2007, 50(15):3416-3419.
148. Bodiwala H.S., Sabde S., Gupta P., Mukherjee R., Kumar R., Garg P., et al. Design and synthesis of caffeoyl-anilides as portmanteau inhibitors of HIV-1 integrase and CCR5. Bioorg. Med. Chem. 2011, 19(3):1256.
149. Wheeler L.A. Silencing sexually transmitted infections: Topical siRNA-based interventions for the prevention of HIV and HSV. Infect. Dis. Obstet. Gynecol. 2014, 2014. (Article ID 125087).
150. Alexandre K.B., Gray E.S., Lambson B.E., Moore P.L., Choge I.A., Mlisana K., et al. Mannose-rich glycosylation patterns on HIV-1 subtype C gp120 and sensitivity to the lectins Griffithsin, Cyanovirin-N and Scytovirin. Virology 2010, 402:187-196.
151. Matoba N., Husk A.S., Barnett B.W., Pickel M.M., Arntzen C.J., Montefiori D.C., et al. HIV-1 neutralization profile and plant-based recombinant expression of actinohivin, an Env glycan-specific lectin devoid of T-cell mitogenic activity. PLoS ONE 2010, 5:e11143.
152. Liu X., Lagenaur L.A., Simpson D.A., Essenmacher K.P., Frazier-Parker C.L., Liu Y., et al. Engineered vaginal lactobacillus strain for mucosal delivery of the human immunodeficiency virus inhibitor cyanovirin-N. Antimicrob. Agents Chemother. 2006, 50:3250-3259.
153. Colgan R., Atkinson C.J., Paul M., Hassan S., Drake P.M., Sexton A.L., et al. Optimisation of contained Nicotiana tabacum cultivation for the production of recombinant protein pharmaceuticals. Transgenic Res. 2010, 19:241-256.
154. Psychoyos A., Creatsas G., Hassan E., Georgoulia V., Gravanis A. Spermicidal and antiviral properties of cholic acid: contraceptive efficacy of a new vaginal sponge (Protectaid®) containing sodium cholate. Hum. Reprod. 1993, 8:866-869.
155. L. Ferguson, J. Cohen, J. Schubert, T. Gong, C. Dezzutti, D. Friend, et al., Vaginal delivery of UC781 in Woman's Condom capsules, Microbicides 2010, Pittsburgh, PA, Abstract no. 248.
156. Vanpouille C., Arakelyan A., Margolis L. Microbicides: still a long road to success. Trends Microbiol. 2012, 20(8):369-375.
157. Barnhart K.T., Rosenberg M.J., MacKay H.T., Blithe D.L., Higgins J., Walsh T., et al. Contraceptive efficacy of a novel spermicidal microbicide used with a diaphragm. Obstet. Gynecol. 2007, 110:577-586.
158. Morris G.C., Lacey C.J. Microbicides and HIV prevention: lessons from the past, looking to the future. Curr. Opin. Infect. Dis. 2010, 23:57-63.
159. Friend D.R., Doncel G.F. Combining prevention of HIV-1, other sexually transmitted infections and unintended pregnancies: development of dual-protection technologies. Antiviral Res. 2010, 88:S47-S54.
160. Friend D.R. Pharmaceutical development of microbicide drug products. Pharm. Dev. Technol. 2010, 15:562-581.
161. Garg S., Goldman D., Krumme M., Rohan L.C., Smoot S., Friend D.R. Advances in development, scale-up and manufacturing of microbicide gels, films, and tablets. Antivir. Res. 2010, 88S:S19-S29.
162. Parikh U.M., Dobard C., Sharma S., Cong M., Jia H., Martin A., et al. Complete protection from repeated vaginal SHIV exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine. J. Virol. 2009, 83:10358-10365.
163. Cohen M.S., Muessig K.E., Smith M.K., Powers K.A., Kashuba A.D.M. Antiviral agents and HIV prevention: controversies, conflicts, and consensus. AIDS 2012, 26:1585-1598.
164. Cost M., Dezzutti C.S., Clark M.R., Friend D.R., Akil A., Rohan L.C. Characterization of UC781-tenofovir combination gel products for HIV-1 infection prevention in an ex vivo ectocervical model. Antimicrob. Agents Chemother. 2012, 56(6):3058-3066.
165. Fernández-Romero J.A., Thorn M., Turville S.G., Titchen K., Sudol K., Li J., et al. Carrageenan/MIV-150 (PC-815), a combination microbicide. Sex. Transm. Dis. 2007, 34:9-14.
166. Hsu M., Aravantinou M., Menon R., Seidor S., Goldman D., Kenney J., et al. A combination microbicide gel protects macaques against vaginal simian human immunodeficiency virus-reverse transcriptase infection, but only partially reduces herpes simplex virus-2 infection after a single high-dose cochallenge. AIDS Res. Hum. Retrovir. 2014, 30(2):174-183.
167. Kizima L., Rodríguez A., Kenney J., Derby N., Mizenina O., Menon R., et al. A potent combination microbicide that targets SHIV-RT, HSV-2 and HPV. PLoS ONE 2014, 16;9(4):e94547.
168. Coggins C., Blanchard K., Alvarez F., Brache V., Weisberg E., Kilmarx P.H., et al. Preliminary safety and acceptability of a carrageenan gel for possible use as a vaginal microbicide. Sex. Transm. Infect. 2000, 76:480-483.
169. Van Damme L., Wright A., Depraetere K., Rosenstein I., Vandersmissen V., Poulter L., et al. A phase I study of a novel potential intravaginal microbicide, PRO 2000, in healthy sexually inactive women. Sex. Transm. Infect. 2000, 76:126-130.
170. Hardy E., Jimenez A.L., de Padua K.S., Zaneveld L.J. Women's preferences for vaginal antimicrobial contraceptives. III. Choice of a formulation, applicator, and packaging. Contraception 1998, 58:245-249.
171. Garg S., Tambwekar K.R., Vermani K., Kandarapu R., Garg A., Walle D.P., et al. Development pharmaceutics of microbicide formulations. Part II: formulation, evaluation, and challenges. AIDS patient care STDS 2003, 17:377-399.
172. Romano J., Malcolm R.K., Garg S., Rohan L., Kaptur P. Microbicide delivery: formulation technologies and strategies. Curr. Opin. HIV AIDS 2008, 3:558-566.
173. Hwu J.R., Tseng W.N., Gnabre J., Giza P., Huang R.C. Antiviral activities of methylated nordihydroguaiaretic acids. 1. Synthesis, structure identification, and inhibition of tat-regulated HIV transactivation. J. Med. Chem. 1998, 41:2994-3000.
174. Khanna N., Dalby R., Connor A., Church A., Stern J., Frazer N. Phase I clinical trial of repeat dose terameprocol vaginal ointment in healthy female volunteers. Sex. Transm. Dis. 2008, 35:577-582.
175. Holt B.Y., Morwitz V.G., Ngo L., Harrison P.F., Whaley K.J., Pettifor A., et al. Microbicide preference among young women in California. J. Women's Health (Larchmt) 2006, 15:281-294.
176. Auslander B.A., Perfect M.M., Breitkopf D.M., Succop P.A., Rosenthal S.L. Microbicides: information, beliefs, and preferences for insertion. J. Womens Health (Larchmt) 2007, 16:1458-1467.
177. das Neves J., Bahia M.F. Gels as vaginal drug delivery systems. Int. J. Pharm. 2006, 318:1-14.
178. Date A.A., Destache C.J. A review of nanotechnological approaches for the prophylaxis of HIV/AIDS. Biomaterials 2013, 34:6202-6228.
179. Garg S., Anderson R.A., Chany C.J., Waller D.P., Diao X.H., Vermani K., et al. Properties of a new acid buffering bioadhesive vaginal formulation. Contraception 2001, 64:67-75.
180. Keller M.J., Carpenter C.A., Lo Y., Einstein M.H., Liu C., Fredricks D.N., et al. Phase I randomized safety study of twice daily dosing of acidform vaginal Gel: Candidate antimicrobial contraceptive. PLoS ONE 2012, 7(10):e46901.
181. Maguire R.A., Zacharopoulos V.R., Phillips D.M. Carrageenan-based nonoxynol-9 spermicides for prevention of sexually transmitted infections. Sex. Transm. Dis. 1998, 25:494-500.
182. Pearce-Pratt R., Phillips D.M. Sulfated polysaccharides inhibit lymphocyte-to-epithelial transmission of human immunodeficiency virus-1. Biol. Reprod. 1996, 54:173-182.
183. Cummins J.E., Guarner J., Flowers L., Guenthner P.C., Bartlett J., Morken T., et al. Preclinical testing of candidate topical microbicides for anti-human immunodeficiency virus type 1 activity and tissue toxicity in a human cervical explant culture. Antimicrob. Agents Chemother. 2007, 51(5):1770-1779.
184. Tao W., Richards C., Hamer D. Enhancement of HIV infection by cellulose sulfate. AIDS Res. Hum. Retrovir. 2008, 24:925-929.
185. Bolognesi N. AIDS gel's failure calls prevention approach into question. Nat. Med. 2007, 13:230.
186. Schwartz J.L., Mauck C., Lai J.J., Creinin M.D., Brache V., Ballagh S.A., et al. Fourteen-day safety and acceptability study of 6% cellulose sulfate gel: a randomized double-blind Phase I safety study. Contraception 2006, 74:133-140.
187. Ballagh S.A., Baker J.M., Henry D.M., Archer D.F. Safety of single daily use for one week of C31G HEC gel in women. Contraception 2002, 66:369-375.
188. Mauck C., Weiner D.H., Ballagh S., Creinin M., Archer D.F., Schwartz J., et al. Single and multiple exposure tolerance study of cellulose sulfate gel: a Phase I safety and colposcopy study. Contraception 2001, 64:383-391.
189. Mayer K.H., Karim S.A., Kelly C., Maslankowski L., Rees H., Profy A.T., et al. Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV uninfected and abstinent HIV-infected women. Aids 2003, 17:321-329.
190. Morrow K., Rosen R., Richter L., Emans A., Forbes A., Day J., et al. The acceptability of an investigational vaginal microbicide, PRO 2000 Gel, among women in a phase I clinical trial. J. Women's Health (Larchmt) 2003, 12:655-666.
191. Mauck C.K., Weiner D.H., Ballagh S.A., Creinin M.D., Archer D.F., Schwartz J.L., et al. Single and multiple exposure tolerance study of polystyrene sulfonate gel: a phase I safety and colposcopy study. Contraception 2004, 70:77-83.
192. Novák C., de la Loge L., van der Meulen E.A. The combined contraceptive vaginal ring NuvaRing: an international study of user acceptability. Contraception 2003, 67:187-194.
193. Drzewinska J., Appelhans D., Voit B., Bryszewska M., Klajnert B. Poly(propylene imine) dendrimers modified with maltose or maltotriose protect phosphorothioate oligodeoxynucleotides against nuclease activity. Biochem. Biophys. Res. Commun. 2012, 427(1):197-201.
194. Nakamura K., Ohtsuki T., Mori H., Hoshino H., Hoque A., Oue A., et al. Novel anti-HIV-1 activity produced by conjugating unsulfated dextran with polyL-lysine. Antivir. Res. 2012, 94(1):89-97.
195. Wang Y., Lee C.H. Characterization of a female controlled drug delivery system for microbicides. Contraception 2002, 66(4):281-287.
196. Cruz O.J.D., Samuel P., Waurzyniak B., Uckun F.M. In vivo evaluation of a gel formulation of stampidine, a novel nonspermicidal broad-spectrum anti-HIV microbicide. Biol. Reprod. 2003, 69:1843-1851.
197. Mourtas S., Fotopoulou S., Duraj S., Sfika V., Tsakiroglou C., Antimisiaris S.G. Liposomal drugs dispersed in hydrogels: effect of liposome, drug and gel properties on drug release kinetics. Colloids Surf. B Biointerfaces 2007, 55(2):212-221.
198. Singh O., Garg T., Rath G., Goyal A.K. Microbicides for the treatment of sexually transmitted HIV infections. J. Pharm. 2014, 2014. (Article ID 352425.).
199. Garg S., Verman K., Anderson R.A., Zaneveld L.J. Rapidly disintegrating novel bioadhesive vaginal tablets of polystyrene sulfonate (PSS), a potential microbicide formulation [abstract]. International conference of AIDS July 11-16 2004, (Abstract No. TuPeB4656.).
200. Garg S., Vermani K., Garg A., Anderson R.A., Rencher W.B., Zaneveld L.J. Development and characterization of bioadhesive vaginal films of sodium polystyrene sulfonate (PSS), a novel contraceptive antimicrobial agent. Pharm. Res. 2005, 22:584-595.
201. Kast C.E., Valenta C., Leopold M., Bernkop-Schnürch A. Design and in vitro evaluation of a novel bioadhesive vaginal drug delivery system for clotrimazole. J. Control. Release 2002, 81(3):347-354.
202. Weber J., Desai K., Darbyshire J. The development of vaginal microbicides for the prevention of HIV transmission. PLoS Med. 2005, 2(5):392-395.
203. Tang C., Yin C., Pei Y., Zhang M., Wu L. New superporous hydrogels composites based on aqueous carbopol® solution (SPHCcs): Synthesis, characterization and in vitro bioadhesive force studies. Eur. Polym. J. 2005, 41:557-562.
204. Valenta C. The use of mucoadhesive polymers in vaginal delivery. Adv. Drug Deliv. Rev. 2005, 57(11):1692-1712.
205. Bonferoni M.C., Giunchedi P., Scalia S., Caramella C. Chitosan gels for the vaginal delivery of lactic acid: Relevance of formulation parameters to mucoadhesion and release mechanisms. AAPS PharmSciTech 2006, 7(4):E1-E8.
206. Ruel-Gariépy E., Leroux J.C. In situ-forming hydrogels-review of temperaturesensitive systems. Eur. J. Pharm. Biopharm. 2004, 58:409-426.
207. Roy S., Gourde P., Piret J., Désormeaux A., Lamontagne J., Haineault C., et al. Thermoreversible gel formulations containing sodium lauryl sulfate or n-Lauroylsarcosine as potential topical microbicides against sexually transmitted diseases. Antimicrob. Agents Chemother. 2001, 45:1671-1681.
208. Podaralla S., Alt C., Shankar G.N. Formulation development and evaluation of innovative two-polymer (SR-2P) bioadhesive vaginal Gel. AAPS Pharm. Sci. Tech. 2014, 15(4):928-938.
209. Owen D.H., Peters J.J., Katz D.F. Comparison of the rheological properties of advantage-S and replens. Contraception 2001, 64:393-396.
210. Thorgeirsdottir T.O., Kjoniksen A.-L., Knudsen K.D., Kristmundsdottir T., Nystrom B. Viscoelastic and structural properties of pharmaceutical hydrogels containing monocarpin. Eur. J. Pharm. Biopharm. 2005, 59:333-342.
211. Mourtas S., Aggelopoulos C., Klepetsanis P., Tsakiroglou C., Antimisiaris S.G. Complex gel formulations for topical drug administration: Rheological properties and aging. Langmuir 2009, 25(15):8480-8488.
212. Tan H., Tam K.C., Jenkins R.D. Relaxation spectra and viscoelastic behavior of a model hydrophobically modified alkali-soluble emulsion (HASE) polymer in salt/SDS solutions. J. Colloid Interface Sci. 2000, 231:52-58.
213. Martinez-Ruvalcaba E., Chornet E., Rodrigue D. Viscoelastic properties of dispersed chitosan/xanthan hydrogels. Carbohydr. Polym. 2007, 67:586-595.
214. Owen D.H., Peters J.J., Lavine M.L., Katz D.F. Effect of temperature and pH on contraceptive gel viscosity. Contraception 2003, 67:57-64.
215. Dezzutti C.S., Rohan L.C., Wang L., Uranker K., Shetler C., Cost M., et al. Reformulated tenofovir gel for use as a dual compartment microbicide. J. Antimicrob. Chemother. 2012, 67:2139-2142.
216. Joshi S., Dutta S., Kumar B.K., Katti U., Kulkarni S., Risbud A., et al. Expanded safety study of praneem polyherbal vaginal tablet among HIV uninfected women in pune, India: A phase II clinical trial report. Sex. Transm. Infect. 2008, 84:343-347.
217. Joglekar N.S., Joshi S.N., Navlakha S.N., Katti U.R., Mehendale S.M. Acceptability of Praneem polyherbal vaginal tablet among HIV uninfected women & their male partners in Pune, India-Phase I study. Indian J. Med. Res. 2006, 123:547-552.
218. Simbar M., Azarbad Z., Mojab F., Majd H.A. A comparative study of the therapeutic effects of the Zataria multiflora vaginal cream and metronidazole vaginal gel on bacterialvaginosis. Phytomedicine 2008, 15(12):1025-1031.
219. Forbes A. Women and HIV. Microbicides for HIV prevention. Bulletin of experimental treatments for AIDS 2006, 18(4):37-41.
220. Elias C., Coggins C. Acceptability research on femalecontrolled barriermethods to prevent heterosexual transmission of HIV: Where have we been? Where are we going. J. Womens Health Gend. Based Med. 2001, 10:163-173.
221. Naswa S., Marfatia Y.S., Prasad T.L. Microbicides and HIV: a review and an update. Indian J. Sex. Transm. Dis. 2012, 33(2):81-90.
222. Veeregowda D.H., Busscher H.J., Vissink A., Jager D.J., Sharma P.K., van der Mei H.C. Role of structure and glycosylation of adsorbed protein films in biolubrication. PLoS ONE 2012, 7(8):e42600.
223. Lu H., Zhao Q., Wallace G., Liu S., He Y., Shattock R., et al. Cellulose acetate 1,2-benzenedicarboxylate inhibits infection by cell-free and cell-associated primary HIV-1 isolates. AIDS Res. Hum. Retrovir. 2006, 22:411-418.
224. Cole A.M., Patton D.L., Rohan L.C., Cole A.L., Cosgrove-Sweeney Y., Rogers N.A., et al. The formulated microbicide RC-101 was safe and antivirally active following intravaginal application in pigtailed macaques. PLoS ONE 2010, e15111.
225. Sassi A.B., Cost M.R., Cole A.L., Cole A.M., Patton D.L., Gupta P., et al. Formulation development of retrocyclin 1 analog RC-101 as an anti-HIV vaginal microbicide product. Antimicrob. Agents Chemother. 2011, 55:2282-2289.
226. Stone A. Microbicides: A new approach to preventing HIV and other sexually transmitted infections. Nat. Rev. Drug Discov. 2002, 1(12):977-985.
227. Van Herrewege Y., Michiels J., Van Roey J., Fransen K., Kestens L., Balzarini J., et al. In vitro evaluation of non-nucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides. Antimicrob. Agents Chemother. 2004, 48(1):337-339.
228. Malcolm R.K., Edwards K.L., Kiser P., Romano J., Smith T.J. Advances in microbicide vaginal rings. Antivir. Res. 2010, 88S:S30-S39.
229. van Damme L., Szpir M. Current status of topical antiretroviral chemoprophylaxis. Curr. Opin. HIV AIDS 2012, 7(6):520-525.
230. Wright R.L., Frost C.J., Turok D.K. A qualitativeexploration of emergency contraception users' willingness to select the copper IUD. Contraception 2012, 85(1):32-35.
231. Saxena B.B., Han Y.A., Fu D., Rathnam P., Singh M., Laurence J., et al. Sustained release of microbicides by newly engineered vaginal rings. AIDS 2009, 23(8):917-922.
232. Malcolm R.K., Fetherston S.M., McCoy C.F., Boyd P., Major I. Vaginal rings for delivery of HIV microbicides. Int. J. Women's Health 2012, 4:595-605.
233. Moore J.P., Shattock R.J. Preventing HIV-1 sexual transmission-not sexy enough science, or no benefit to the bottom line?. J. Antimicrob. Chemother. 2003, 52:890-892.
234. Woolfson A.D., Malcom R.K., Morrow R.J., Tonner C.F., Mc Cullag S.D. Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicides. Int. J. Pharm. 2006, 325(1-2):82-89.
235. Oddsson K., Leifels-Fischer B., de Melo N.R., Wiel-Masson D., Benedetto C., Verhoeven C.H., et al. Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: a 1-year randomized trial. Contraception 2005, 71:176-182.
236. Malcolm K., Woolfson D., Russell J., Andrews C. In vitro release of nonoxynol-9 from silicone matrix intravaginal rings. J. Control. Relat. 2003, 91:355-364.
237. Malcolm K., Woolfson D., Russell J., Tallon P., McAuley L., Craig D. Influence of silicone elastomer solubility and diffusivity on the in vitro release of drugs from intravaginal rings. J. Control. Relat. 2003, 90:217-225.
238. Koetsawang S., Gao J., Krishna U., Cuadros A., Dhall G.I., Wyss R., et al. Microdose intravaginal contraception: A mulicentre clinical trial: I Contraceptive efficacy and side effects. Contraception 1990, 41:105-124.
239. Weisberg E., Fraser I.S., Baker J., Archer D., Landgren B.M., Killick S., et al. A randomized comparison of the effects on vaginal and cervical epithelium of a placebo vaginal ring with non-use of a ring. Contraception 2000, 62(2):83-89.
240. Schafer J.E., Osborne L.M., Davis A.R., Westhoff C. Acceptability and satisfaction using Quick Start with the contraceptive vaginal ring versus an oral contraceptive. Contraception 2006, 73:488-492.
241. Fine P.M., Tyrggestad J., Meyeres N.J., Sangi-Haghpeykar H. Safety and acceptability with the use of a contraceptive vaginal ring after surgical or medical abortion. Contraception 2007, 75:367-371.
242. Brucker C., Karck U., Merkle E. Cycle control, tolerability, efficacy and acceptability of the vaginal contraceptive ring, NuvaRing®: Results of clinical experience in Germany. Eur. J. Contracept. Reprod. Health 2008, 13:31-38.
243. Gilliam M.L., Neustadt A., Kozloski M., Mistretta S., Tilmon S., Godfrey E. Adherence and acceptability of the contraceptive ring compared with the pill Among students: A randomized controlled trial. Obstet. Gynecol. 2010, 115:503-510.
244. Wang Y., Lee H.C. Effects of intrinsic variables on release of sodium dodecyl sulfate from a female controlled drug delivery system. Int. J. Pharm. 2004, 282(1-2):173-181.
245. Nel A., Smythe S., Young K., Malcolm K., McCoy C., Rosenberg Z., et al. Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women. J. Acquir. Immune Defic. Syndr. 2009, 51:416-423.
246. Gupta K.M., Pearce S.M., Poursaid A.E., Aliyar H.A., Tresco P.A., Mitchnik M.A., et al. Polyurethane intravaginal ring for controlled delivery of dapivirine, a nonnucleoside reverse transcriptase inhibitor of HIV-1. J. Pharm. Sci. 2008, 97(10):4228-4239.
247. Bell S.E., Dennis A.C., Fido L.A., Malcolm R.K., Sirimuthu N.M., Toner C.F., et al. Characterization of silicone elastomer vaginal rings containing HIV microbicide TMC120 by Raman spectroscopy. J. Pharm. Pharmacol. 2007, 59:203-207.
248. Romano J., Variano B., Coplan P., Van Roey J., Douville K., Rosenberg Z., et al. Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring. AIDS Res. Hum. Retrovir. 2009, 25:483-488.
249. Prabhu P., Patravale V. The upcoming field of theranostic nanomedicine: An overview. J. Biomed. Nanotechnol. 2012, 8(6):859-882.
250. Sampathkumar K., Arulkumar S., Ramalingam M. Advances in stimuli responsive nanobiomaterials for cancer therapy. J. Biomed. Nanotechnol. 2014, 10(3):367-382.
251. Desai P., Date A.A., Patravale V.B. Overcoming poor oral bioavailability using nanoparticle formulations e opportunities and limitations. Drug Discov. Today Technol. 2012, 9:87-95.
252. Ruckmani K., Sankar V., Sivakumar M. Tissue distribution, pharmacokinetics and stability studies of zidovudine delivered by niosomes and proniosomes. J. Biomed. Nanotechnol. 2010, 6(1):43-51.
253. Da Silva P.B., Ramos M.A.D.S., Bonifácio B.V., Negri K.M.S., Sato M.R., Bauab T.M.B., et al. Nanotechnological strategies for vaginal administration of drugs - A review. J. Biomed. Nanotechnol. 2014, 10(9):2218-2243.
254. du Toit L.C., Pillay V., Choonara Y.E. Nano-microbicides: challenges in drug delivery, patient ethics and intellectual property in the war against HIV/AIDS. Adv. Drug Deliv. Rev. 2010, 62:532-546.
255. Mourtas S., Haikou M., Theodoropoulou M., Tsakiroglou C., Antimisiaris S.G. How liposome type, composition and loading concentration influence the rheological properties of a liposomal gel. J. Colloid Interface Sci. 2008, 317(2):611-619.
256. Mourtas S., Duraj S., Fotopoulou S., Antimisiaris S.G. Integrity of liposomes in presence of various formulation additives, in aqueous dispersions and in hydrogels. Colloids Surf. B: Biointerfaces 2008, 61(2):270-276.
257. Chonco L., Pion M., Vacas E., Rasines B., Maly M., Serramía M.J., et al. Carbosilane dendrimer nanotechnology outlines of the broad HIV blocker profile. J. Control. Release 2012, 161:949-958.
258. Córdoba E.V., Arnáiz E., De La Mata F.J., Gómez R., Leal M., Pion M., et al. Synergistic activity of carbosilane dendrimers in combination with maraviroc against HIV in vitro. AIDS 2013, 27(13):2053-2058.
259. Córdoba E.V., Arnaiz E., Relloso M., Sánchez-Torres C., García F., Pérez-Álvarez L., et al. Development of sulphated and naphthylsulphonated carbosilane dendrimers as topical microbicides to prevent HIV-1 sexual transmission. AIDS 2013, 27(8):1219-1229.
260. Sepúlveda-Crespo D., Lorente R., Leal M., Gómez R., De la Mata F.J., Jiménez J.L., et al. Synergistic activity profile of carbosilane dendrimer G2-STE16 in combination with other dendrimers and antiretrovirals as topical anti-HIV-1 microbicide. Nanomedicine 2014, 10(3):609-618.
261. Han S., Yoshida D., Kanamoto T., Nakashima H., Uryu T., Yoshida T. Sulfated oligosaccharide cluster with polylysine core scaffold as a new anti-HIV dendrimer. Carbohydr. Polym. 2010, 80:1111-1115.
262. Han S., Kanamoto T., Nakashima H., Yoshida T. Synthesis of a new amphiphilic glycodendrimer with antiviral functionality. Carbohydr. Polym. 2012, 90:1061-1068.
263. Dutta T., Jain N.K. Targeting potential and anti-HIV activity of lamivudine loaded mannosylated poly (propyleneimine) dendrimer. Biochim. Biophys. Acta 2007, 1770:681-686.
264. Dutta T., Garg M., Jain N.K. Targeting of efavirenz loaded tuftsin conjugated poly(propyleneimine) dendrimers to HIV infected macrophages in vitro. Eur. J. Pharm. Sci. 2008, 34:181-189.
265. Weber N., Ortega P., Clemente M.I., Shcharbin D., Bryszewska M., de la Mata F.J., et al. Characterization of carbosilane dendrimers as effective carriers of siRNA to HIV-infected lymphocytes. J. Control. Release 2008, 132:55-64.
266. Navath R.S., Menjoge A.R., Dai H., Romero R., Kannan S., Kannan R.M. Injectable PAMAM dendrimer-PEG hydrogels for the treatment of genital infections: formulation and in vitro and in vivo evaluation. Mol. Pharm. 2011, 8:1209-1223.
267. Ham A., Cost M., Sassi A., Dezzutti C., Rohan L. Targeted delivery of PSC-RANTES for HIV-1 prevention using biodegradable nanoparticles. Pharm. Res. 2009, 26(3):502-511.
268. Cu Y., Booth C.J., Saltzman W.M. In vivo distribution of surface-modifed PLGA nanoparticles following intravaginal delivery. J. Control. Release 2011, 156:258-264.
269. Ensign L.M., Tang B.C., Wang Y.Y., Tse T.A., Hoen T., Cone R., et al. Mucus-penetrating nanoparticles for vaginal drug delivery protect against herpes simplex virus. Sci. Transl. Med. 2012, 4:138-179.
270. Zhang T., Sturgis T.F., Youan B.B. pH-responsive nanoparticles releasing tenofovir intended for the prevention of HIV transmission. Eur. J. Pharm. Biopharm. 2011, 79:526-536.
271. Yoo J.W., Giri N., Lee C.H. pH-sensitive Eudragit nanoparticles for mucosal drug delivery. Int. J. Pharm. 2011, 403:262-267.
272. Meng J., Sturgis T.F., Youan B.B. Engineering tenofovir loaded chitosan nanoparticles to maximize microbicide mucoadhesion. Eur. J. Pharm. Sci. 2011, 44:57-67.
273. Belletti D., Tosi G., Forni F., Gamberini M.C., Baraldi C., Vandelli M.A., et al. Chemico-physical investigation of tenofovir loaded polymeric nanoparticles. Int. J. Pharm. 2012, 436:753-763.
274. Date A.A., Shibata A., Goede M., Sanford B., La Bruzzo K., Belshan M., et al. Development and evaluation of a thermosensitive vaginal gel containing raltegravir+efavirenz loaded nanoparticles for HIV prophylaxis. Antiviral Res. 2012, 96:430-436.
275. Shibata A., McMullen E., Pham A., Belshan M., Sanford B., Zhou Y., et al. Polymeric nanoparticles containing combination antiretroviral drugs for HIV type 1 treatment. AIDS Res. Hum. Retrovir. 2013, 29(5):746-754.
276. Chaowanachan T., Krogstad E., Ball C., Woodrow K.A. Drug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxis. PLoS ONE 2013, 8(4):e61416.
277. das Neves J., Araújo F., Andrade F., Michiels J., Ariën K.K., Vanham G., Amiji M., et al. In vitro and ex vivo evaluation of polymeric nanoparticles for vaginal and rectal delivery of the anti-HIV drug dapivirine. Mol. Pharm. 2013, 10(7):2793-2807.
278. das Neves J., Araújo F., Andrade F., Amiji M., Bahia M.F., Sarmento B. Biodistribution and pharmacokinetics of dapivirine-loaded nanoparticles after vaginal delivery in mice. Pharm. Res. 2014, 31(7):1834-1845.
279. Ramana L.N., Sharma S., Sethuraman S., Ranga U., Krishnan U.M. Evaluation of chitosan nanoformulations as potent anti-HIV therapeutic systems. Biochim. Biophys. Acta 2014, 1840:476-484.
280. Park J.H., Saravanakumar G., Kim K., Kwon I.C. Targeted delivery of low molecular drugs using chitosan and its derivatives. Adv. Drug Deliv. Rev. 2010, 62:28-41.
281. Agrahari V., Zhang C., Zhang T., Li W., Gounev T.K., Oyler N.A., et al. Hyaluronidase-sensitive nanoparticle templates for triggered release of HIV/AIDS microbicide in vitro. AAPS J. 2014, 16(2):181-193.
282. Antimisiaris S.G., Kallinteri P., Fatouros D.G. Liposomes and drug delivery. Pharmaceutical manufacturing handbook: Production and processes 2008, John Wiley & Sons, Inc, Hoboken, NJ, USA. S.C. Gad (Ed.).
283. Stolte-Leeb N., Loddo R., Antimisiaris S., Schultheiss T., Sauermann U., Franz M., et al. Topical nonnucleoside reverse transcriptase inhibitor MC 1220 partially prevents vaginal RT-SHIV infection of macaques. AIDS Res. Hum. Retrovir. 2011, 27(9):933-943.
284. Mourtas S., Mao J., Parsy C.C., Storer R., Klepetsanis P., Antimisiari S.G. Liposomal Gels for vaginal delivery of the microbicide MC-1220: Preparation and in vivo vaginal toxicity and pharmacokinatics. Nano LIFE 2010, 1:195-205.
285. Wang L., Sassi A.B., Patton D., Isaacs C., Moncla B.J., Gupta P., et al. Development of a liposome microbicide formulation for vaginal delivery of octylglycerol for HIV prevention. Drug Dev. Ind. Pharm. 2012, 38(8):995-1007.
286. Malavia N.K., Zurakowski D., Schroeder A., Princiotto A.M., Laury A.R., Barash H.E., et al. Liposomes for HIV prophylaxis. Biomaterials 2011, 32:8663-8668.
287. Almeida A.J., Souto E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv. Drug Deliv. Rev. 2007, 59(6):478-490.
288. Alukda D., Sturgis T., Youan B.B. Formulation of tenofovir-loaded functionalized solid lipid nanoparticles intended for HIV prevention. J. Pharm. Sci. 2011, 100:3345-3356.
289. Ball C., Krogstad E., Chaowanachan T., Woodrow K.A. Drug-eluting fibers for HIV-1 inhibition and contraception. PLoS ONE 2012, 7:e49792.
290. Patravale V.B., Date A.A., Kulkarni R.M. Nanosuspensions: a promising drug delivery strategy. J. Pharm. Pharmacol. 2004, 56:827-840.
291. Baert L., van't Klooster G., Dries W., François M., Wouters A., Basstanie E., et al. Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment. Eur. J. Pharm. Biopharm. 2009, 72:502-508.
292. Bowman M.C., Ballard T.E., Ackerson C.J., Feldheim D.L., Margolis D.M., Melander C. Inhibition of HIV fusion with multivalent gold nanoparticles. J. Am. Chem. Soc. 2008, 130:6896-6897.
293. Di Gianvincenzo P., Marradi M., Martínez-Avila O.M., Bedoya L.M., Alcamí J., Penadés S. Gold nanoparticles capped with sulfate-ended ligands as anti-HIV agents. Bioorg. Med. Chem. Lett. 2010, 20:2718-2721.
294. Vijayakumar S., Ganesan S. Gold nanoparticles as an HIV entry inhibitor. Curr. HIV Res. 2012, 10:643-646.
295. Shiang Y.C., Ou C.M., Chen S.J., Ou T.Y., Lin H.J., Huang C.C., et al. Highly efficient inhibition of human immunodeficiency virus type 1 reverse transcriptase by aptamers functionalized gold nanoparticles. Nanoscale 2013, 5:1678-1686.
296. Marradi M., Di Gianvincenzo P., Enríquez-Navas P.M., Martínez-Ávila O.M., Chiodo F., Yuste E., Angulo J., Penadés S. Gold nanoparticles coated with oligomannosides of HIV-1 glycoprotein gp120 mimic the carbohydrate epitope of antibody 2G12. J. Mol. Biol. 2011, 410:798-810.
297. Lara H.H., Ayala-Nuñez N.V., Ixtepan-Turrent L., Rodriguez-Padilla C. Mode of antiviral action of silver nanoparticles against HIV-1. J. Nanobiotechnol. 2010, 8:1.
298. Vasilyeva S.V., Silnikov V.N., Shatskaya N.V., Levina A.S., Repkova M.N., Zarytova V.F. SiO2 nanoparticles as platform for delivery of nucleoside triphosphate analogues into cells. Bioorg. Med. Chem. 2013, 21:703-711.
299. Uskokovic V., Uskokovic D.P. Nanosized hydroxyapatite and other calcium phosphates: chemistry of formation and application as drug and gene delivery agents. J. Biomed. Mater. Res. B Appl. Biomater. 2011, 96:152-191.
300. Symonds G.P., Johnstone H.A., Millington M.L., Boyd M.P., Burke B.P., Breton L.R. The use of cell-delivered gene therapy for the treatment of HIV/AIDS. Immunol. Res. 2010, 48:84-98.
301. Zeller S.J., Kumar P. RNA-based gene therapy for the treatment and prevention of HIV: from bench to bedside. Yale J. Biol. Med. 2011, 84:301-309.
302. Yang S., Chen Y., Ahmadie R., Ho E.A. Advancements in the field of intravaginal siRNA delivery. J. Control. Release 2013, 167:29-39.
303. (Accessed 6-9-2014). http://www.unaids.org.
304. (Accessed 6-9-2014). http://apps.who.int/rhl/hiv_aids/nscom1/en/index.html.
305. (Accessed 3-9-2014). http://clinicaltrials.gov/show/NCT00130078.
306. (Accessed 1-9-2014). http://www.conrad.org/f-3.html.
307. (Accessed 1-9-2014). http://www.conrad.org/news-pressreleases-10.html.
308. (Accessed 1-9-2014). http://clinicaltrialsfeeds.org/clinical-trials/results/term=Carraguard+PC-515.
309. (Accessed 1-9-2014). http://www.conrad.org/news-pressreleases-16.html.
310. (Accessed 1-9-2014). http://www.conrad.org/news-pressreleases-42.html.
311. (accessed 1-9-2014). http://www.mtnstopshiv.org/studies/64.
312. (accessed 2-9-2014). http://img.thebody.com/gcm/pdfs/pipeline0908.pdf.
313. (Accesed 2-9-2014). http://www.clinicaltrials.gov/ct2/show/NCT00594373.
314. (Accesed 2-9-2014). http://www.mtnstopshiv.org/news/studies/mtn002/backgrounder.
315. (Accessed 6-9-2014). http://www.mtnstopshiv.org/news/studies/mtn008.
316. (Accesed 2-9-2014). http://www.conrad.org/microbicides-trials.html.
317. (Accesed 2-9-2014). http://www.conrad.org/media/news/92_CAPRISA%20004%20Results.pdf.
318. (Accesed 2-9-2014). http://www.avac.org/caprisa-008.
319. (Accesed 2-9-2014). http://www.conrad.org/microbicides-trials.html.
320. (Accesed 2-9-2014). http://www.mtnstopshiv.org/news/studies/mtn003.
321. (Accessed 3-9-2014). http://www.mtnstopshiv.org/node/4844.
322. (Accessed 1-9-2014). http://www.mdp.mrc.ac.uk/publications_documents/MDP%20302%20Design_15Nov10.pdf.
323. (Accessed 1-9-2014). http://www.iavireport.org/Back-Issues/Pages/IAVI-Report-14(5)-VaccineBriefs.aspx.
324. (Accesed 2-9-2014). http://www.facts-consortium.co.za/?page_id=83.
325. (Accesed 2-9-2014). http://www.conrad.org/news-pressreleases-72.html.
326. (Accessed 3-9-2014). http://www.ipmglobal.org/our-work/research/ipm-012.
327. (Accessed 3-9-2014). http://www.ipmglobal.org/our-work/research/ipm-014a.
328. (Accessed 3-9-2014). http://www.ipmglobal.org/our-work/research/ipm-020.
329. (Accessed 3-9-2014). http://www.ipmglobal.org/our-work/research/ipm-014b.
330. (Accessed 3-9-2014). http://www.ipmglobal.org/our-work/research/ipm-024.
331. (Accessed 3-9-2014). http://www.ipmglobal.org/sites/default/files/attachments/IPM_AnnualReport_FINAL-LRes.pdf.
332. (Accessed 3-9-2014). http://www.ipmglobal.org/our-work/research/ipm-015.
333. (Accessed 3-9-2014). http://www.ipmglobal.org/our-work/research/ipm-027-ring-study-0.
334. (Accessed 3-9-2014). http://www.mtnstopshiv.org/node/5862.
335. (Accessed 3-9-2014). http://www.ipmglobal.org/our-work/research/ipm-013.
336. (Accessed 3-9-2014). http://www.mtnstopshiv.org/news/studies/mtn013.
337. (Accessed 3-9-2014). http://www.sciencedaily.com/releases/2014/03/140304125927.htm.
338. (Accessed 3-9-2014). http://ichgcp.net/clinical-trials-registry/NCT00441909.
339. (Accessed 3-9-2014). http://www.mtnstopshiv.org/studies/1619.
340. HIV TREATMENT BULLETIN, Preventive technologies: antiretroviral and vaccine development, 19 July 2014, (accesed 5-9-2014). http://i-base.info/htb/26951.
341. (Accessed in 3-9-2014). http://www.mtnstopshiv.org/studies.
342. (Accessed in 3-9-2014). http://clinicaltrials.gov/ct2/show/NCT01242579.
343. (Accessed in 6-9-2014). http://www.ipmglobal.org/sites/default/files/Clinical_Trials_Fact_Sheet_MAR-14.pdf.
344. (Accessed 6-9-2014). http://www.aidsinfo.nih.gov.
345. http://mpts101.org/mpt-database.
346. (Accessed 6-9-2014). http://www.avac.org/prevention-option/microbicides.